<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antituberculous drugs: An overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antituberculous drugs: An overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antituberculous drugs: An overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Drew, PharmD, MS, FCCP, FIDP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy R Sterling, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic agents for treatment of tuberculosis (TB) are utilized in a hierarchical fashion [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p>
         First-line agents for treatment of TB disease consist of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin (
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or [less frequently] either
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ; in addition,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         is a first-line agent when administered in combination with isoniazid, rifapentine, and pyrazinamide [
         <a href="#rid6">
          6
         </a>
         ]. Dosing for first-line agents for treatment of TB disease in adults is summarized in the tables  (
         <a class="graphic graphic_table graphicRef55978" href="/z/d/graphic/55978.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef131747" href="/z/d/graphic/131747.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Presence of drug resistance, contraindication, or intolerance to first-line agents may warrant substitution with one or more second-line agents. Categories of second-line agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef119120" href="/z/d/graphic/119120.html" rel="external">
          table 3
         </a>
         ). Dosing for second-line agents is summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). Further details regarding treatment of multidrug-resistant TB are provided in guidelines published by the American Thoracic Society [
         <a href="#rid2">
          2
         </a>
         ] and the World Health Organization [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Pharmacologic issues and some clinical data related to use of antituberculous drugs are reviewed here; issues related to clinical use of antituberculous drugs in therapeutic regimens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">
          "Tuberculosis disease in children: Treatment and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2848506435">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         TB terminology is inconsistent in the literature [
         <a href="#rid7">
          7
         </a>
         ]. Relevant terms are defined in the table  (
         <a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1525201709">
         <span class="h1">
          FIRST-LINE AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-line antituberculous agents for treatment of susceptible TB consist of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin (usually
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         (when administered in combination with isoniazid,
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         , and pyrazinamide). The clinical approach to use of these agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">
          "Tuberculosis disease in children: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         Dosing for first-line agents is summarized in the tables  (
         <a class="graphic graphic_table graphicRef55978" href="/z/d/graphic/55978.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef131747" href="/z/d/graphic/131747.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Issues related to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/481.html" rel="external">
          "Isoniazid: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/477.html" rel="external">
          "Isoniazid hepatotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/316.html" rel="external">
          "Isoniazid (INH) poisoning"
         </a>
         .)
        </p>
        <p>
         Issues related to
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and the other rifamycins are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)"
         </a>
         .)
        </p>
        <p>
         Issues related to
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/478.html" rel="external">
          "Ethambutol: An overview"
         </a>
         .)
        </p>
        <p>
         Issues related to
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/492.html" rel="external">
          "Pyrazinamide: An overview"
         </a>
         .)
        </p>
        <p>
         Issues related to use of
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         in a shortened four-month regimen are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2739502074">
         <span class="h1">
          SECOND-LINE AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of drug resistance, contraindications, or intolerance to first-line antituberculous agents warrants use of second-line agents. These agents are so classified because of decreased activity against
         <em>
          Mycobacterium tuberculosis
         </em>
         , relative lack of clinical data, unfavorable or poorly characterized pharmacokinetic profile, and/or increased incidence and severity of adverse events compared with first-line agents [
         <a href="#rid1">
          1,8
         </a>
         ].
        </p>
        <p>
         Selection of second-line antituberculous agents should be guided by in vitro susceptibility results with involvement of an expert in the treatment of TB. In the setting of severe illness, treatment with second-line agents may need to be initiated prior to availability of drug susceptibility results. In such cases, treatment decisions should be based on the drug susceptibility pattern of the source case to whom the patient has been exposed, prior treatment regimens of the patient (ie, agents that have not been used previously are preferred), and the likelihood of cross-resistance based on previous agents used  (
         <a class="graphic graphic_table graphicRef119120" href="/z/d/graphic/119120.html" rel="external">
          table 3
         </a>
         ). Dosing and adverse effects for second-line agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). The clinical approach to use of second-line agents is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4230170009">
         <span class="h2">
          Oral agents
         </span>
        </p>
        <p class="headingAnchor" id="H674311480">
         <span class="h3">
          Bedaquiline
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         is an oral diarylquinoline drug with bactericidal antituberculous activity approved by the US Food and Drug Administration (FDA) in 2012 for treatment of multidrug-resistant (MDR)-TB. Guidelines regarding its use were published by the United States Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) [
         <a href="#rid3">
          3,9
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         has become an important option for the treatment of drug-resistant pulmonary TB. It may be used as part of combination therapy for treatment of pulmonary, MDR-TB via directly observed therapy as part of combination therapy when an effective treatment regimen cannot otherwise be provided [
         <a href="#rid3">
          3
         </a>
         ]. The approach to use of bedaquiline for treatment of drug-resistant TB is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/135189.html" rel="external">
          "Tuberculosis disease in children: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         The CDC issued 2013 guidelines for
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         use in populations not included in the clinical trials for the drug (and hence not covered by the FDA approval), including children, pregnant women, individuals with extrapulmonary MDR-TB, and individuals with HIV or other comorbid conditions [
         <a href="#rid9">
          9
         </a>
         ]. The CDC indicated that bedaquiline may be used on a case-by-case basis for these individuals when an effective treatment regimen cannot otherwise be provided. The WHO 2020 guidelines concluded
         <em>
         </em>
         no major safety concerns for bedaquiline (&gt;6 months’ duration), the use of bedaquiline with delamanid, or bedaquiline use during pregnancy [
         <a href="#rid3">
          3
         </a>
         ].
         <em>
         </em>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         can cause QT prolongation, leading to cardiac arrhythmia and/or death. In data submitted to the FDA, death was observed more frequently among patients receiving bedaquiline than among those treated with other antituberculous agents (11.4 versus 2.5 percent) [
         <a href="#rid10">
          10
         </a>
         ]. However, in subsequent larger clinical studies, bedaquiline appeared to be safer than in the initial trials [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         Patients on
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         should be monitored for symptoms of cardiac toxicity and by electrocardiogram (ECG) [
         <a href="#rid13">
          13
         </a>
         ]. An ECG should be obtained at baseline and repeated at least 2, 12, and 24 weeks after starting treatment, as well as in the setting of syncope. Weekly ECGs are warranted for patients with increased risk of QT prolongation (this includes patients with history of torsade de pointes, congenital long QT syndrome, hypothyroidism, bradyarrhythmia, uncompensated heart failure, as well as patients on other QTc-prolonging drugs  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 6
         </a>
         )). Discontinuation of bedaquiline is warranted in the setting of clinically significant ventricular arrhythmia or QTc F &gt;500 ms. Serum potassium, calcium, and magnesium should be obtained at baseline and monitored until fully corrected.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         is a cytochrome P450 substrate; therefore, coadministration with strong CYP3A4 inducers (such as
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ) or inhibitors should be avoided whenever possible.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         has a terminal serum half-life of four to five months [
         <a href="#rid14">
          14,15
         </a>
         ]. To minimize the likelihood of bedaquiline resistance, it may be discontinued prior to other active drugs; at least three other agents should be included for the remainder of treatment [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Cross-resistance between
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         and
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         has been observed via mutation in the
         <em>
          Rv0678
         </em>
         regulatory gene, resulting in upregulation of an efflux pump [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3961284767">
         <span class="h3">
          Clofazimine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          Clofazimine
         </a>
         is a semisynthetic riminophenazine postulated to disrupt electron transport and generate reactive oxygen species [
         <a href="#rid19">
          19
         </a>
         ]. In general, the availability of clofazimine is limited to regions where it is used for the treatment of leprosy [
         <a href="#rid20">
          20
         </a>
         ]. In the United States, use of clofazimine for treatment of drug-resistant TB requires submission of an investigational new drug application to the FDA.
        </p>
        <p>
         Adverse effects of
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         include photosensitivity, brownish skin discoloration, ichthyosis, QT prolongation, neurologic, and gastrointestinal (GI) intolerance [
         <a href="#rid21">
          21
         </a>
         ]. Caution is warranted when administering clofazimine with other agents that may also cause QT prolongation  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         Cross-resistance between
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         and
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         has been observed via mutation in the
         <em>
          Rv0678
         </em>
         regulatory gene, resulting in upregulation of an efflux pump [
         <a href="#rid16">
          16,17
         </a>
         ]. Therefore, in patients who have failed a regimen with one of these drugs, it may be prudent to avoid use of the other.
        </p>
        <p class="headingAnchor" id="H3942237411">
         <span class="h3">
          Cycloserine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          Cycloserine
         </a>
         disrupts peptidoglycan synthesis as a competitive inhibitor of alanine racemase and D-alanine:D-alanine ligase [
         <a href="#rid22">
          22
         </a>
         ]. It should be administered via dose escalation over a two-week period as summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). A study observed that such dosing for cycloserine (250 to 500 mg once or twice daily) would likely be inadequate for isolates with MICs &gt;16 mcg/mL [
         <a href="#rid23">
          23
         </a>
         ]. Divided dosing had no negative impact on attaining target exposure but could potentially reduce cycloserine-induced adverse effects. Serum drug concentrations should be monitored for all patients on cycloserine [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Serum drug concentration monitoring'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          Cycloserine
         </a>
         may be associated with neuropsychiatric adverse reactions; therefore, it should be used with caution in patients with pre-existing mental health issues. When possible, cycloserine should also be avoided in patients with a history of seizure disorder. Peripheral neuropathy is common in patients taking cycloserine and is more commonly observed in patients with impaired drug clearance [
         <a href="#rid24">
          24
         </a>
         ].
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          Pyridoxine
         </a>
         25 to 50 mg/day may be coadministered in attempts to prevent neuropathy; however, data are lacking regarding efficacy. Higher doses of pyridoxine (150 to 200 mg/day) in patients receiving cycloserine have been associated with an increased risk of neuropathy [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Central nervous system toxicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3349430936">
         <span class="h3">
          Delamanid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delamanid is an oral nitro-dihydro-imidazo-oxazole drug that inhibits mycolic acid synthesis [
         <a href="#rid25">
          25,26
         </a>
         ]. It has been conditionally approved for use in the treatment of MDR-TB by the European Medicines Agency but has not yet received FDA approval for use in the United States [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Delamanid may be used in TB treatment regimens among adults with pulmonary MDR-TB when an effective and well-tolerated regimen cannot be composed with conventional second-line drugs. Patients for whom delamanid may be particularly useful include those with increased risk for poor outcomes (such as drug intolerance or contraindication, extensive or advanced disease, resistance to fluoroquinolones and/or aminoglycosides/
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         , and extensively drug-resistant [XDR] TB) [
         <a href="#rid26">
          26,28
         </a>
         ].
        </p>
        <p>
         Delamanid is a substrate of CYP3A4; therefore, caution should be exercised in patients receiving CYP3A4 inducers (such as
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ) and inhibitors (such as
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         ).
        </p>
        <p>
         Delamanid can cause QT prolongation, leading to cardiac arrhythmia and/or death; caution is warranted when administering delamanid with other agents that may cause QT prolongation  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 6
         </a>
         ). In one study, combining delamanid with
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         was associated with only modest (no more than additive) QTc prolongation [
         <a href="#rid29">
          29
         </a>
         ]. The WHO 2020 guidelines concluded
         <em>
         </em>
         no major safety concerns for use of bedaquiline with delamanid [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2037393614">
         <span class="h3">
          Ethionamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          Ethionamide
         </a>
         may be used for treatment of drug-resistant TB if the isolate is known to be susceptible to ethionamide via conventional in vitro testing or if molecular testing demonstrates no evidence of mutations in the
         <em>
          inhA
         </em>
         gene, since mutations in this gene can confer resistance to ethionamide (in addition to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         resistance) [
         <a href="#rid5">
          5
         </a>
         ]. In the setting of known isoniazid resistance and in the absence of confirmed ethionamide susceptibility, use of ethionamide should be deferred.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          Ethionamide
         </a>
         should be administered via dose escalation over a two-week period as summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). However, it is uncertain whether such dosing obtains the targeted drug exposures needed for efficacy [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         is likely to cause hypothyroidism as well as GI side effects. Patients may tolerate one of these two drugs but may not tolerate both together. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1909960362">
         <span class="h3">
          Fluoroquinolones: levofloxacin or moxifloxacin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluoroquinolones have excellent activity in vitro against
         <em>
          M. tuberculosis
         </em>
         and represent the initial category of second-line antituberculous agents in the setting of resistance and/or intolerance to first-line agents [
         <a href="#rid32">
          32,33
         </a>
         ]. In addition,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         is a first-line agent when administered in combination with
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'
         </a>
         .)
        </p>
        <p>
         In general,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         are favored over the early-generation fluoroquinolones (specifically
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) for treatment of TB, due to greater in vitro activity [
         <a href="#rid34">
          34-42
         </a>
         ]. In one study including 834 patients with suspected drug-resistant TB, mortality rates among those treated with either moxifloxacin or levofloxacin were half those of participants not treated with any fluoroquinolone or treated only with an earlier-generation fluoroquinolone (adjusted hazard ratio 0.46, 95% CI 0.26-0.80) [
         <a href="#rid41">
          41
         </a>
         ]. Since all fluoroquinolones share a genetic target (deoxyribonucleic acid [DNA] gyrase), there is no role for simultaneous use of more than one drug in this class [
         <a href="#rid43">
          43-45
         </a>
         ].
        </p>
        <p>
         Cross-resistance between fluoroquinolones is common but not universal [
         <a href="#rid5">
          5,46
         </a>
         ]. When fluoroquinolone resistance is detected by culture-based drug susceptibility testing or molecular testing, an MIC for
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         may be performed to determine whether an increased dose may be considered. Use of "high-dose" moxifloxacin (600 mg or 800 mg orally once daily) may achieve adequate serum concentrations in patients for whom the isolate's MIC to moxifloxacin is 1 to 2 mcg/mL. However, this approach has not been studied in clinical trials, and the safety of such dose escalations has not been established [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The fluoroquinolones are generally well-tolerated. Rare complications include tenosynovitis (including reports of Achilles tendinitis and rupture) and exacerbation of symptoms among patients with myasthenia gravis and peripheral neuropathy [
         <a href="#rid47">
          47,48
         </a>
         ].
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         is less frequently associated with QT interval prolongation than
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         (standard dose), so levofloxacin may be preferred for patients on a regimen including other agents associated with QT prolongation (including
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         ,
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         , and delamanid)  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). Moxifloxacin does not require dose adjustment in patients with renal insufficiency (unlike levofloxacin).
        </p>
        <p>
         Data supporting use of higher doses of
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         (1000 mg/day) come from a small randomized trial and a pharmacokinetic study [
         <a href="#rid49">
          49-51
         </a>
         ]. In a previous trial including 182 patients with MDR-TB randomized to receive either levofloxacin (750 mg/day) or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         (with a background drug regimen), both drugs were associated with high rates of culture conversion at three months [
         <a href="#rid35">
          35
         </a>
         ]. Prior to these studies, data on levofloxacin administered at a lower dose (500 mg/day) suggested that levofloxacin was less effective than moxifloxacin or
         <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">
          gatifloxacin
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Additional issues related to fluoroquinolones are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2005160708">
         <span class="h3">
          Linezolid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          Linezolid
         </a>
         may be used for treatment of MDR- and XDR-TB or in settings of intolerance to other drugs [
         <a href="#rid52">
          52
         </a>
         ]. It should be used with caution and close monitoring as its use is often limited by adverse effects such as bone marrow suppression, neuropathy, GI symptoms, and/or retinitis [
         <a href="#rid53">
          53-59
         </a>
         ]. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p>
         Development of
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         toxicity should prompt dose reduction (eg, from 600 to 300 mg orally once daily). In such cases, a serum drug concentration should be measured to ensure the concentration is within the therapeutic range. In addition, studies have suggested that such dose reductions will not likely obtain the target drug exposure needed for efficacy [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          Linezolid
         </a>
         should not be administered concomitantly with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), or a diet high in tyramine-containing foods (such as cheese, red wine, cured meats, soy sauce, and fermented foods), given the risk of serotonin syndrome. If linezolid therapy is planned and when possible, SSRIs and TCAs should be withdrawn at least two weeks in advance (given the long half-lives of these agents).
        </p>
        <p>
         In one report including 41 patients with XDR-TB in South Korea, sputum cultures converted to negative after addition of
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         in 87 percent of cases [
         <a href="#rid58">
          58
         </a>
         ]. Significant cumulative toxicity was observed, including peripheral neuropathy at low and high doses of linezolid (60 percent at 300 mg/day and 80 percent at 600 mg/day). These rates are significantly higher than those observed in patients receiving linezolid for other indications.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          Linezolid
         </a>
         has been evaluated in combination with
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         and
         <a class="drug drug_general" data-topicid="122334" href="/z/d/drug information/122334.html" rel="external">
          pretomanid
         </a>
         for treatment of highly resistant TB. In general, this regimen should be considered in MDR-TB patients with resistance to fluoroquinolones and no previous exposure to bedaquiline and linezolid for &gt;2 weeks [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Bedaquiline, pretomanid, linezolid'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4065039376">
         <span class="h3">
          Para-aminosalicylic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          Para-aminosalicylic acid
         </a>
         (not available in the United States or Canada) is bacteriostatic; it has limited efficacy for treatment of TB and is poorly tolerated (due to GI and endocrine side effects [including hypothyroidism], particularly when administered in combination with
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          Para-aminosalicylic acid
         </a>
         should be administered via dose escalation over a two-week period as summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         is likely to cause hypothyroidism as well as GI side effects. Patients may tolerate one of these two drugs but may not tolerate both together. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H712768539">
         <span class="h3">
          Pretomanid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="122334" href="/z/d/drug information/122334.html" rel="external">
          Pretomanid
         </a>
         , a nitroimidazole, has bactericidal activity [
         <a href="#rid62">
          62-64
         </a>
         ]. A regimen of pretomanid,
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         , and high-dose
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         has FDA approval for treatment of patients with XDR-TB or treatment-intolerant or nonresponsive MDR-TB. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1153264332">
         <span class="h3">
          Thioacetazone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thioacetazone has bacteriostatic activity against TB. Toxicity is high, and its use should be restricted to cases with broad resistance. Thioacetazone should not be administered to patients with HIV infection; such patients are at increased risk for drug-induced Stevens-Johnson syndrome [
         <a href="#rid65">
          65
         </a>
         ]. Thioacetazone is not available in the United States, and reliable formulations are unavailable in many areas.
        </p>
        <p class="headingAnchor" id="H1180933787">
         <span class="h2">
          Injectable-only agents
         </span>
        </p>
        <p class="headingAnchor" id="H3350816006">
         <span class="h3">
          Aminoglycosides and capreomycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-line injectable-only agents for treatment of TB include aminoglycosides (
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         , kanamycin) and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         (a polypeptide). In general, amikacin is the preferred agent (due to general availability of the drug and serum concentration monitoring). Use of streptomycin is generally restricted to the setting of known in vitro susceptibility (given high rates of drug resistance), no history of prior use, and contraindication to amikacin. Kanamycin and capreomycin are no longer recommended by the WHO for use in MDR-TB regimens [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         There is no role for use of more than one of these injectable agents in a treatment regimen, given their common mechanism of action (eg, protein synthesis inhibition) [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
         Cross-resistance among the injectable-only agents has been observed and may be helpful in predicting use of alternate agents in the setting of prior injectable exposure (pending definitive susceptibility data) [
         <a href="#rid66">
          66-71
         </a>
         ]. Cross-resistance between
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         is incomplete, while streptomycin-resistant isolates are often susceptible to other aminoglycosides or capreomycin (unless they have been used previously).
        </p>
        <p>
         Second-line injectable-only agents can be given either intramuscularly or intravenously. For patients who cannot tolerate repeated intramuscular injections, intravenous therapy may be administered. They are typically given five days per week; they should be administered seven days per week for patients who are severely ill. The initial duration of daily therapy (referred to as the "intensive phase" of treatment) is administered until culture conversion is documented (at least two to three months and can be up to six months). After culture conversion, three-days-per-week dosing can be used for the remaining duration (referred to as the "continuation phase" of treatment [normally through at least six months and up to 18 months beyond culture conversion]).
        </p>
        <p>
         Serum drug concentration monitoring is warranted for all aminoglycosides and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         given their potential for nephrotoxicity and consequent electrolyte disorders [
         <a href="#rid72">
          72
         </a>
         ]. In addition, the aminoglycosides can cause eighth cranial nerve damage. Renal function should be assessed regularly, and audiometry performed on a monthly basis. (See
         <a class="local">
          'Serum drug concentration monitoring'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">
          "Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H303130486">
         <span class="h3">
          Carbapenems plus clavulanate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          M. tuberculosis
         </em>
         is resistant to beta-lactam antibiotics in vitro, but resistance may be overcome in some isolates by inhibiting the beta-lactamase with clavulanate [
         <a href="#rid73">
          73
         </a>
         ]. The combination of carbapenems (either imipenem-cilastatin or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         ) with clavulanate (a beta-lactamase inhibitor) has been shown to be bactericidal against
         <em>
          M. tuberculosis
         </em>
         , and some clinical efficacy has been observed in a small number of patients [
         <a href="#rid74">
          74-76
         </a>
         ]. However, data from controlled clinical trials to evaluate safety and efficacy of such treatment are lacking.
        </p>
        <p>
         Use of carbapenems is limited by high cost, intravenous administration, and limited clinical experience. Use of
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         once daily intramuscularly or intravenous administration may be considered in place of imipenem-cilastatin or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         for patients continuing carbapenem therapy in an outpatient setting [
         <a href="#rid2">
          2
         </a>
         ]. Since clavulanate is not available as a single formulation, coadministration of
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         is required to provide 125 mg of the clavulanate for each carbapenem dose.
        </p>
        <p class="headingAnchor" id="H1439257899">
         <span class="h1">
          DIRECTLY OBSERVED THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with TB should receive directly observed therapy (DOT) when available as part of patient-centered case management [
         <a href="#rid1">
          1
         </a>
         ]. This is most important in those receiving intermittent therapy and in special populations (such as patients with HIV, homeless patients, or patients otherwise at high risk of treatment failure). Ideally, DOT should occur seven days per week. If this is not possible, five-days-per-week DOT may be used for patients who are not hospitalized, with self-administration of medications on weekends during the induction phase or before the patient becomes smear negative. Subsequently, treatment may be five days per week via DOT. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2176535244">
         <span class="h1">
          SERUM DRUG CONCENTRATION MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monitoring of serum concentrations for antituberculous therapy is warranted for select patients as summarized below (in settings where serum drug concentrations can be obtained). Data to establish a target range associated with efficacy are lacking for many agents; rather, target concentrations are based on the known pharmacodynamics of the agent, exposures in normal volunteers, as well as serum concentrations observed during clinical trials. While such monitoring does not ensure clinical success, it does provide guidance for dose adjustments to optimize drug efficacy and safety.
        </p>
        <p>
         Antituberculous serum drug concentration monitoring should be pursued in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-resistant tuberculosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of clinical response or relapse while on appropriate drugs administered via directly observed therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known or suspected drug malabsorption (eg, underlying diabetes mellitus with gastroparesis, alcohol use, select gastrointestinal disorders)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regimen with potentially significant drug-drug interactions, such as combination of rifamycins and select antiretrovirals (most notably protease inhibitors)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe renal impairment (including those receiving renal replacement therapy) for agents with significant renal clearance
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV coinfection (especially those with low CD4 lymphocyte counts and those receiving antiretrovirals known to interact with antituberculous therapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of aminoglycosides,
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antituberculous regimen with few effective drugs (to optimize the effect of the available drugs)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of antituberculous doses lower than standard therapy because of drug intolerance or higher (due to prior failure to reach adequate drug exposures)
        </p>
        <p>
        </p>
        <p>
         Serum drug concentration monitoring should be performed following initiation of treatment or regimen adjustments, after steady-state concentrations have been achieved. In patients with delayed absorption, serum concentrations obtained two hours after the dose may fail to accurately characterize drug absorption. To address this concern, collecting samples two and six hours after drug administration may be used to evaluate the extent and rate of drug absorption [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         The target peak concentrations, intervals between drug administration, and serum collection times for therapeutic monitoring of antituberculous drugs are summarized in the table  (
         <a class="graphic graphic_table graphicRef109278" href="/z/d/graphic/109278.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2348124906">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
        </p>
        <p class="headingAnchor" id="H2636671244">
         <span class="h2">
          Clinical and laboratory monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of patients with tuberculosis requires careful monitoring for adverse drug effects. This is especially important when second-line agents are used and/or when drug doses are escalated.
        </p>
        <p>
         Patients receiving combination antituberculous therapy should undergo baseline measurement of liver function tests (serum bilirubin, alkaline phosphatase, and transaminases). In addition, testing for hepatitis B and C should be pursued for patients with epidemiologic risk factors [
         <a href="#rid78">
          78
         </a>
         ]. Counseling and testing for HIV infection should also be performed. Other baseline tests prior to initiation of antituberculous therapy should include complete blood count, creatinine, and uric acid [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Patients on regimens including drugs associated with hepatotoxicity (notably
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         ) should be counseled to avoid use of alcohol and drugs associated with hepatotoxicity (such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ). Patients should be educated about the signs and symptoms of hepatic toxicity. These include anorexia, nausea, vomiting, dark urine, icterus, rash, pruritus, fatigue, fever, abdominal discomfort (particularly right upper quadrant discomfort), easy bruising or bleeding, and arthralgias [
         <a href="#rid79">
          79
         </a>
         ]. Patients should be questioned directly at monthly visits for these symptoms and should know to immediately report any signs or symptoms that occur in the interval between the monthly visits. Patients should also be assessed for symptoms of peripheral neuropathy. All symptomatic patients should be evaluated clinically and have liver function tests performed.
        </p>
        <p>
         Serial liver function measurements are not necessary for patients with normal baseline results and no risk for hepatitis. Monthly liver function tests are warranted in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal baseline liver function tests
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected drug reaction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underlying liver disease (such as viral hepatitis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy and the first three months postpartum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         in continuation phase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other situations that may be associated with hepatic injury (eg, some medications, alcohol or drug abuse)
        </p>
        <p>
        </p>
        <p>
         Issues related to hepatoxicity associated with antituberculous drugs are discussed below and separately. (See
         <a class="local">
          'Hepatotoxicity'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p>
         Additional clinical and laboratory monitoring should be tailored to the treatment regimen. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          Ethambutol
         </a>
         or
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         – Monitor visual acuity and red-green color discrimination (monthly). Vision disturbance may occur related to ethambutol-induced optic nerve dysfunction; however, vision changes should also prompt consideration of tuberculous meningitis under the appropriate circumstances. (See
         <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">
          "Tuberculous meningitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycosides or
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         – Monitor renal function, electrolytes (potassium, calcium, magnesium), and signs of ototoxicity monthly (including audiology testing and evaluation for tinnitus and vestibular toxicity).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          Ethionamide
         </a>
         or para-aminosalicylate – Monitor thyroid stimulating hormone (every three months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          Cycloserine
         </a>
         – Monitor for psychiatric symptoms, particularly depression and mood changes (monthly).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          Linezolid
         </a>
         – Monitor blood counts (weekly during initial phase, then monthly) and for signs and symptoms of peripheral neuropathy and retinitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          Bedaquiline
         </a>
         , fluoroquinolones,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , delamanid – Monitor electrocardiogram (at least 2, 12, and 24 weeks following initiation of treatment, and up to weekly if these agents are used in combination or patient has other risk factors) for QTc prolongation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H464788134">
         <span class="h2">
          Manifestations and their management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antituberculous drugs are associated with a broad array of adverse effects, as discussed by system in the following sections. Some adverse effects may be managed symptomatically with continuation of the drug, some may be managed with dose adjustment and careful monitoring, and some require drug discontinuation with broad reconsideration of the treatment regimen. Patients should be counseled regarding frequent and/or severe adverse effects and ways to minimize such reactions. Timing of administration (relative to food or bedtime) may help to minimize some adverse effects. Expert consultation should be sought in complex situations.
        </p>
        <p class="headingAnchor" id="H2543311944">
         <span class="h3">
          Gastrointestinal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of antituberculous agents may be associated with gastrointestinal (GI) symptoms. These include (but are not limited to)
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , and
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         .
        </p>
        <p>
         Patients with GI complaints should be evaluated clinically and a differential diagnosis should be considered based on signs and symptoms. Strategies for management of GI symptoms attributed to antituberculous drugs include judicious symptomatic management (ie, use of antiemetics, antidiarrheals, treatment of reflux [note that antacids cannot be given within two hours of fluoroquinolones]), minimizing other GI irritants (such as nonsteroidal anti-inflammatory agents), spacing medications during the day, administering the causative agent at bedtime, administering medication following a light snack, and encouraging hydration.
        </p>
        <p>
         It may be possible to make drug dose adjustments, as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          Ethionamide
         </a>
         and
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         – Ethionamide often causes upper GI symptoms such as nausea and vomiting, while para-aminosalicylic acid causes lower GI symptoms (such as abdominal cramping and diarrhea); however, symptoms may overlap. Patients may not tolerate both together.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If either
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         or
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         is suspected of causing GI symptoms, both drugs may be held for 3 to 4 days. If the symptoms improve off the medication, they may be restarted (1 drug at a time) at a lower dose (often in 2 or 3 daily administrations), and gradually increased over the next 2 weeks. Ethionamide may be initiated at 250 mg daily and increased to at least 500 mg daily. Para-aminosalicylic acid may be initiated at 2 to 4 grams daily and increased to 6 to 8 grams daily. Patients may tolerate a higher dose of ethionamide in the evening (such as 250 mg in the morning and 500 mg at bedtime). Once the titration is complete, steady-state serum drug concentrations should be monitored to determine whether the concentration is therapeutic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          Linezolid
         </a>
         – If linezolid is suspected of causing GI symptoms, the dose may be reduced from 600 mg to 300 mg orally once daily. In such cases, a serum concentration should be measured to document whether the concentration is therapeutic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          Clofazimine
         </a>
         – If clofazimine is suspected of causing nausea/vomiting, the dose may be reduced to 100 mg orally once daily.
        </p>
        <p>
        </p>
        <p>
         Drug doses for fluoroquinolones should not be reduced. Fluoroquinolones are a critical class in the treatment regimen of drug-resistant tuberculosis (TB), and the bactericidal effects are dose dependent. In addition, antacids containing magnesium, aluminum, or calcium may reduce fluoroquinolone absorption and should be avoided within two to four hours of the fluoroquinolone dose.
        </p>
        <p>
         Drug doses for
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         should not be adjusted pending further data regarding this agent.
        </p>
        <p class="headingAnchor" id="H1340042691">
         <span class="h4">
          Hepatotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal complaints may represent antituberculous hepatotoxicity. Antituberculous drugs associated with hepatotoxicity include
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         . Antituberculous drugs not commonly associated with hepatotoxicity include
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , aminoglycosides, and
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         . Rarely, fluoroquinolones (
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ) have been associated with acute liver injury.
        </p>
        <p>
         Patients on regimens including drugs associated with hepatotoxicity should be counseled to avoid use of alcohol and drugs associated with hepatotoxicity (such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ). Risk factors for drug-induced liver injury include underlying liver disease (particularly hepatitis C) and coadministration of antiretroviral therapy for patients with HIV infection.
        </p>
        <p>
         The approach to management of hepatotoxicity associated with antituberculous drugs should be guided by liver function test results and the agent(s) most suspected of causing such results  (
         <a class="graphic graphic_algorithm graphicRef109447" href="/z/d/graphic/109447.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef139067" href="/z/d/graphic/139067.html" rel="external">
          algorithm 2
         </a>
         ). In general, all hepatotoxic drugs should be discontinued if the serum bilirubin is ≥3 mg/dL (≥51 mcmol/L) or serum transaminases are more than five times the upper limit of normal.
        </p>
        <p>
         Once liver function tests return to baseline (or fall to less than twice normal), potentially hepatotoxic drugs can be restarted one at a time with careful monitoring between resumption of each agent. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2689476426">
         <span class="h3">
          Dermatologic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermatologic reactions secondary to antituberculous therapy may range from mild local effects (not requiring treatment or modification of therapy) to a manifestation of a severe, life-threatening reaction. Antituberculous drugs should be discontinued in the setting of systemic symptoms, fever, mucous membrane involvement, blistering, edema of the lips or eyes, wheezing, or airway compromise.
        </p>
        <p>
         Dermatologic reactions associated with antituberculous drugs include (see
         <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">
          "Drug eruptions"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maculopapular rash and pruritus
         </strong>
         – All antituberculous drugs may cause a maculopapular rash and/or pruritus, some of which resolve after several weeks despite treatment continuation. Other sources of such symptoms should be explored. Mild reactions may be managed symptomatically (with antihistamines or topical corticosteroids) with continuation of the drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hives (urticaria)
         </strong>
         – Hives (urticaria) may be caused by any antituberculous drug. With anti-TB drugs, hives can occur with or without fever. The drug that most commonly causes this type of reaction is
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , followed by
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         , and
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         . Fluoroquinolones and
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         have also been implicated, but the frequency compared with the other drugs is not reported. In children, this presentation may occur during a coincident viral infection (eg, Epstein-Barr or herpes simplex), and the child should be examined for other signs of viral infection and a complete blood count obtained for possible lymphocytosis. All potentially responsible drugs should be stopped until the reaction resolves, although, if a child is found to have evidence of viral infection, all medications can be resumed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In all adults and in children without evidence of a viral infection, rechallenge is recommended for the purpose of identifying the drug responsible for the reaction and resuming the other medications. Rechallenge is appropriate only if the reaction was not severe and there was no evidence of anaphylaxis (ie, concomitant angioedema, hoarse voice, throat tightness, sudden-onset cough, wheezing, mental status change, nausea or vomiting, lightheadedness, or hypotension). Rechallenge is also contraindicated if the patient's reaction had features of Stevens-Johnson syndrome, toxic epidermal necrolysis, or systemic hypersensitivity syndromes such as drug reaction with eosinophilia and systemic symptoms (DRESS), as detailed below. (See
         <a class="local">
          'Severe systemic reactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rechallenge should be performed with one medication at a time, at approximately four-day intervals. A protocol used in the Philadelphia Tuberculosis Control Program is provided  (
         <a class="graphic graphic_table graphicRef108538" href="/z/d/graphic/108538.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flushing
         </strong>
         – Flushing (in the absence of rash, with or without redness and watering of the eyes) within two to three hours of drug administration is most often associated with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         . The reaction is usually mild and self-limited; if bothersome, it may be managed with an antihistamine. Flushing with or without hot flashes, palpitations, or headache two to three hours after consuming tyramine-containing foods (such as cheese, red wine, cured meats, soy sauce, and fermented foods) may be observed in patients taking
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         . This can generally be managed with avoidance of the precipitating foods.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Photosensitivity and hyperpigmentation
         </strong>
         – Patients on
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , or fluoroquinolones are at increased risk for photosensitivity, which may persist for prolonged periods even after the causative drug is stopped. Patients receiving these agents should limit sun exposure and use sunscreen.
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         has been associated with pseudojaundice (brownish discoloration of the skin with clear sclera and normal liver enzymes). Clofazimine-induced hyperpigmentation may also worsen with sun exposure but is usually reversible upon drug discontinuation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lichenoid reactions
         </strong>
         – Several antituberculous drugs (most notably
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         ) can cause lichenoid reactions (pruritic, violaceous papules most commonly involve the wrists, shins, and back). Mucous membranes and scalp may also be involved. Lesions may resolve while medication continues, and medication should not be discontinued unless an equally effective drug is available for substitution. (See
         <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">
          "Lichenoid drug eruption (drug-induced lichen planus)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Superficial fungal infection
         </strong>
         – Cutaneous or mucocutaneous candidiasis secondary to fluoroquinolones and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         occurs more commonly in diabetics and generally responds to topical antifungal therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alopecia
         </strong>
         – Temporary alopecia has been reported in patients receiving
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         or
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Antituberculous drugs should be discontinued in the setting of systemic symptoms, fever, mucous membrane involvement, blistering, edema of the lips or eyes, wheezing, or airway compromise.
        </p>
        <p class="headingAnchor" id="H4235330657">
         <span class="h3">
          Severe systemic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe systemic reactions associated with antituberculous drugs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anaphylaxis
         </strong>
         – Anaphylaxis is rare and presents within minutes of medication dosing as urticaria, angioedema, pruritus, hypotension, and respiratory symptoms. (See
         <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">
          "Anaphylaxis: Acute diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drugs suspected to have caused anaphylaxis should be discontinued. Rechallenge should not be attempted. The patient should be referred to an allergy specialist for possible desensitization utilizing facilities equipped to respond to the potential for life-threatening anaphylaxis. Skin testing for immunoglobulin (Ig)E using the primary drug is almost never useful because the hepatic metabolism of these medications produces neoantigens that are not present in the original drug. Oral desensitization protocols have been published for
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         [
         <a href="#rid80">
          80,81
         </a>
         ] and can be devised for almost any drug. Issues related to drug desensitization are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug reaction with eosinophilia and systemic symptoms
         </strong>
         – DRESS (also known as drug-induced hypersensitivity syndrome [DIHS]) is a rare but potentially life-threatening syndrome secondary to the administration of antituberculous medications (most commonly
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ). Signs and symptoms (usually beginning two to eight weeks after drug initiation) can include fever, malaise, lymphadenopathy, rash, facial edema, mucous membrane involvement, and liver function abnormalities. Once a drug has been identified as the causative agent, it should be discontinued. Rechallenge should not be attempted. Issues related to DRESS are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stevens-Johnson syndrome and toxic epidermal necrolysis
         </strong>
         – These are severe mucocutaneous reactions characterized by drug-induced extensive necrosis and detachment of the epidermis. Once a drug has been identified as the causative agent, it should be discontinued. Rechallenge should not be attempted. These entities are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H746378586">
         <span class="h3">
          QT prolongation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs associated with QT interval prolongation include
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , delamanid, and fluoroquinolones (especially
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ). Patients on these drugs should have regular electrocardiograms (baseline, at two weeks, and then at least monthly) to monitor for QTc prolongation; more frequent monitoring is warranted for patients on multiple QTc-prolonging drugs or in the setting of risk factors. In addition, such patients should have electrolytes checked regularly (baseline, at two weeks, and then at least monthly). (See
         <a class="local">
          'Bedaquiline'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H181482160">
         <span class="h3">
          Neurotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Forms of neurotoxicity associated with antituberculous drugs include peripheral neuropathy and central nervous system toxicity (including psychiatric effects, seizures, and serotonin syndrome).
        </p>
        <p>
         Perioral numbness (transient, nonprogressive) has been reported in patients receiving
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         ; it may be managed with dose and/or interval reduction accompanied by serum drug concentration monitoring to assure target concentrations are achieved.
        </p>
        <p class="headingAnchor" id="H1440104940">
         <span class="h4">
          Peripheral neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antituberculous drugs most commonly associated with peripheral neuropathy include
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         . Fluoroquinolones and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         have rarely been associated with peripheral neuropathy.
        </p>
        <p>
         The likelihood of neuropathy is increased in patients with diabetes, alcoholism, HIV infection, hypothyroidism, pregnancy, and poor nutrition (with inadequate dietary intake of
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         ).
        </p>
        <p>
         If dietary intake of vitamin B6 is insufficient (less than 0.5 to 2 mg daily for children and adults),
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         should be administered to patients on regimens including
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         [
         <a href="#rid82">
          82
         </a>
         ]. Patients on a standard regimen for treatment of drug-susceptible TB should receive pyridoxine 50 mg daily. Patients on treatment for multidrug-resistant TB should receive pyridoxine 100 mg daily. Higher doses of pyridoxine have been associated with an increased risk of peripheral neuropathy and are not recommended routinely [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Neuropathy associated with
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         usually occurs after four months of therapy but can occur earlier. In some patients, symptoms may respond if linezolid doses of 600 mg once daily are reduced (to 300 or 450 mg once daily or 600 mg three to four times weekly) with serum concentration monitoring performed to ensure therapeutic concentrations are achieved.
        </p>
        <p>
         Symptomatic treatment of peripheral neuropathy with neuroleptics (such as
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , or low-dose tricyclic antidepressants) may facilitate the continuation of therapy in some patients.
        </p>
        <p class="headingAnchor" id="H142244298">
         <span class="h4">
          Central nervous system toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Forms of central nervous system toxicity associated with antituberculous drugs include psychiatric effects, seizures, and serotonin syndrome.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychiatric effects
         </strong>
         – Drug-induced depression can occur with
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and (less frequently)
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         or
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         . In patients on cycloserine or ethionamide, depression may be severe and accompanied by suicidal ideation requiring drug discontinuation. Patients with depression should have a serum drug concentration obtained, and the dose should be reduced if feasible  (
         <a class="graphic graphic_table graphicRef109278" href="/z/d/graphic/109278.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with suicidal ideation who are on
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         should have these drugs discontinued. Mild depression may be managed with continuation of therapy and supportive care. Antidepressants may be used, but patients on
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         may not take selective serotonin reuptake inhibitors or tricyclic antidepressants (due to the risk of serotonin syndrome).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug-induced psychosis has been reported with the use of
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , fluoroquinolones, and (less frequently)
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         . Patients with psychosis should be treated with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (100 mg if not already given) along with antipsychotic therapy. Cycloserine should be discontinued and a serum drug concentration obtained. Some patients may tolerate cycloserine with an antipsychotic drug if no other treatment options are available. Cycloserine may be restarted at a lower dose with titration guided by serum drug concentration monitoring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures
         </strong>
         – Drug-induced seizures can occur with
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , fluoroquinolones,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , and carbapenems. These drugs should be discontinued in patients with seizures. Patients on cycloserine should have a serum drug concentration obtained. (See
         <a class="medical medical_review" href="/z/d/html/316.html" rel="external">
          "Isoniazid (INH) poisoning", section on 'Seizure management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients should be treated with anticonvulsant therapy for the duration of the treatment regimen. Once seizures have resolved, medications may be restarted one at a time. Patients with suspected isoniazid-induced seizures who resume
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         should take concomitant
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         .
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          Cycloserine
         </a>
         should be restarted only if it is absolutely essential.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serotonin syndrome
         </strong>
         – Serotonin syndrome may result from the coadministration of
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         with a serotonin reuptake inhibitor, a tricyclic antidepressant, or a diet high in tyramine-containing foods (such as cheese, wine, cured meats, soy sauce, and fermented foods). Signs and symptoms include clonus, agitation, tremor, and/or hyperthermia. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1519203842">
         <span class="h3">
          Ototoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         can cause vestibular and auditory toxicity, even if serum drug concentrations are within the therapeutic range. Toxicity is related to the total dose and is cumulative. (See
         <a class="local">
          'Injectable-only agents'
         </a>
         above.)
        </p>
        <p>
         Patients receiving these agents should have monthly assessments for vestibular and auditory toxicity. Symptoms attributed to the injectable agent (such as tinnitus, unsteadiness, or hearing loss) should prompt elimination of the entire drug class and rechallenge should not be attempted.
        </p>
        <p>
         For patients with fullness in the ears (which may be an early symptom of vestibular toxicity), the dosing interval may be reduced from daily to three times a week (after three to four months of treatment with negative sputum cultures).
        </p>
        <p class="headingAnchor" id="H1904404537">
         <span class="h3">
          Nephrotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         can cause nephrotoxicity and electrolyte disturbances. Patients receiving these drugs should have weekly serum creatinine monitoring for the first several weeks, then at least monthly, in addition to monthly electrolyte monitoring (potassium, calcium and magnesium) with repletion as needed. The optimal frequency of serum drug concentration monitoring for injectable agents is uncertain; it is often performed weekly during the initial phase of treatment (while on daily therapy) and any time there are changes in serum creatinine or following dose adjustments.
        </p>
        <p>
         Drug dose adjustments should be made for patient with renal dysfunction  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1957523183">
         <span class="h3">
          Hematologic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic abnormalities associated with antituberculous drugs (notably
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ) may involve any cell line  (
         <a class="graphic graphic_table graphicRef108484" href="/z/d/graphic/108484.html" rel="external">
          table 9
         </a>
         ). It may be difficult to differentiate abnormalities due to antituberculous therapy from hematologic effects due to TB or other underlying diseases.
        </p>
        <p>
         Hematologic abnormalities in patients receiving treatment for TB may reflect comorbid diseases such as renal insufficiency, nutritional deficiency, malignancy, HIV infection, or bone marrow suppression due to other drugs. They may also occur as a result of bone marrow involvement associated with TB.
        </p>
        <p>
         If other causes are excluded, TB drugs associated with hematologic abnormalities should be discontinued until counts have recovered; thereafter, the drugs should restarted one at a time with close hematologic monitoring. Drug(s) associated with recurrent hematologic abnormalities should not be continued.
        </p>
        <p>
         When hematologic toxicity due to
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         is mild and resolves off therapy, linezolid may be resumed at a lower dose (eg, 300 mg instead of 600 mg). In such settings, monitoring of serum concentrations is necessary to assure adequate therapeutic concentrations.
        </p>
        <p class="headingAnchor" id="H213242118">
         <span class="h3">
          Ophthalmic toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antituberculous drugs associated with optic nerve toxicity include
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         .
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          Clofazimine
         </a>
         toxicity produces a pigmentary maculopathy and generalized retinal degeneration. Ophthalmic toxicity associated with these agents should prompt ophthalmology referral and drug discontinuation.
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         can cause a pan-uveitis that is reversible with holding therapy and resumption with dose adjustment.
        </p>
        <p>
         Patients taking
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         should be monitored monthly for ophthalmic symptoms, which can be dose and duration related. Monthly visual acuity and color discrimination evaluation is warranted for patients receiving ethambutol (≥25 mg/kg) and/or patients receiving the drug for longer than two months.
        </p>
        <p class="headingAnchor" id="H2835012353">
         <span class="h3">
          Musculoskeletal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myalgias and arthralgias are common in patients taking antituberculous therapy and may be associated with
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , fluoroquinolones,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         . These manifestations do not warrant drug discontinuation and may reflect drug-induced electrolyte disturbances or thyroid dysfunction.
        </p>
        <p>
         Tendonitis and tendon rupture have been associated with fluoroquinolone use. The drug may be continued in the setting of mild tendon inflammation but should be discontinued in the setting of significant inflammation.
        </p>
        <p class="headingAnchor" id="H3203422607">
         <span class="h3">
          Endocrine effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine effects associated with antituberculous drugs include hypothyroidism, gynecomastia, and dysglycemia.
        </p>
        <p>
         Hypothyroidism may develop with
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         or
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ; when used in combination, the incidence of hypothyroidism may be ≥40 percent [
         <a href="#rid5">
          5
         </a>
         ]. Patients on these drugs should have baseline and monthly thyroid function assessment. When thyroid stimulating hormone rises to &gt;1.5 times the upper limit of normal, thyroid hormone replacement should be initiated. (See
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p>
         Gynecomastia can occur in patients on
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ; the drug may be continued and gynecomastia resolves when treatment is stopped.
        </p>
        <p>
         Hypoglycemia has been associated with
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         . Fluoroquinolones, particularly
         <a class="drug drug_general" data-topicid="8928" href="/z/d/drug information/8928.html" rel="external">
          gatifloxacin
         </a>
         (no longer available in the United States for this reason), can cause hypoglycemia or hyperglycemia.
        </p>
        <p class="headingAnchor" id="H2739577118">
         <span class="h3">
          Other adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Miscellaneous adverse effects are summarized below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metallic taste
         </strong>
         – Metallic taste can occur in patients on
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         or fluoroquinolones. Patients should be encouraged to tolerate this side effect, which resolves when treatment is stopped.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flu-like syndrome
         </strong>
         – Flu-like syndrome has been reported with
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         . The rifamycins can cause a flu-like syndrome beginning one to two hours after administration and resolving six to eight hours later. Typically, this syndrome occurs more commonly with intermittent rather than daily therapy, particularly at higher doses. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H364567930">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">
          "Society guideline links: Diagnosis and treatment of tuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4044566">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line agents
         </strong>
         – First-line agents for treatment of tuberculosis (TB) consist of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (or
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         in certain situations),
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         . Dosing for first-line agents is summarized in the table  (
         <a class="graphic graphic_table graphicRef55978" href="/z/d/graphic/55978.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef131747" href="/z/d/graphic/131747.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'First-line agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-line agents
         </strong>
         – Presence of drug resistance or intolerance to first-line agents warrants use of second-line agents. These agents are so classified because of relative lack of clinical data, unfavorable or poorly characterized pharmacokinetic profile, and/or increased incidence and severity of adverse events. Categories of second-line agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef119120" href="/z/d/graphic/119120.html" rel="external">
          table 3
         </a>
         ). Antituberculous agents should be used in combination for treatment of TB disease, guided by in vitro susceptibility results and selected with involvement of an expert in the treatment of TB. Dosing for second-line agents is summarized in the table  (
         <a class="graphic graphic_table graphicRef66493" href="/z/d/graphic/66493.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Second-line agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoroquinolones
         </strong>
         – In general,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         are favored over the early-generation fluoroquinolones for treatment of TB. There is no role for use of more than one fluoroquinolone in a treatment regimen since all drugs in the class share a genetic target. Cross-resistance between fluoroquinolones is common but not universal. (See
         <a class="local">
          'Fluoroquinolones: levofloxacin or moxifloxacin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical and laboratory monitoring
         </strong>
         – Patients receiving antituberculous therapy should undergo baseline measurement of liver function tests (serum bilirubin, alkaline phosphatase, and transaminases). Serial liver function measurements are not necessary for patients with normal baseline results and no risk for hepatitis; monthly liver function tests should be obtained in the clinical settings outlined above. (See
         <a class="local">
          'Clinical and laboratory monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic drug monitoring
         </strong>
         – Indications for therapeutic drug monitoring include (but are not limited to) use of injectable-only agents or
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , presence of renal impairment, and regimens with potentially significant drug-drug interactions  (
         <a class="graphic graphic_table graphicRef109278" href="/z/d/graphic/109278.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Serum drug concentration monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal effects
         </strong>
         – Gastrointestinal symptoms may be associated with a number of antituberculous agents, including
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10341" href="/z/d/drug information/10341.html" rel="external">
          para-aminosalicylic acid
         </a>
         (the latter two particularly in combination),
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , and
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         . Strategies include symptomatic management; it may be possible to make drug dose adjustments in some cases. (See
         <a class="local">
          'Gastrointestinal effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatotoxicity
         </strong>
         – Management of hepatotoxicity should be guided by liver function test results  (
         <a class="graphic graphic_algorithm graphicRef109447" href="/z/d/graphic/109447.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef139067" href="/z/d/graphic/139067.html" rel="external">
          algorithm 2
         </a>
         ). In general, all hepatotoxic drugs should be discontinued if the serum bilirubin is ≥3 mg/dL (≥51 mcmol/L) or serum transaminases are more than five times the upper limit of normal. Thereafter, once liver function tests return to baseline (or fall to less than twice normal), potentially hepatotoxic drugs can be restarted one at a time with careful monitoring between resumption of each agent. (See
         <a class="local">
          'Hepatotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermatologic effects
         </strong>
         – Dermatologic reactions associated with antituberculous drugs include maculopapular rash (any antituberculous drug), flushing (
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         ), photosensitivity (pyrazinamide,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , or fluoroquinolones), lichenoid reactions (
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         ), and hives (any antituberculous drug). (See
         <a class="local">
          'Dermatologic effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe systemic reactions
         </strong>
         – Severe systemic reactions associated with antituberculous drugs include anaphylaxis, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Antituberculous drugs should be discontinued in the setting of systemic symptoms, fever, urticaria, mucous membrane involvement, blistering, edema of the lips or eyes, wheezing, or airway compromise. Referral to an allergist with experience in drug allergy should be considered for more severe reactions. (See
         <a class="local">
          'Severe systemic reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          QT prolongation
         </strong>
         – Drugs associated with QT interval prolongation include
         <a class="drug drug_general" data-topicid="87509" href="/z/d/drug information/87509.html" rel="external">
          bedaquiline
         </a>
         ,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , delamanid, and fluoroquinolones  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 6
         </a>
         ). Patients on these drugs should have regular electrocardiograms (baseline, at two weeks, and then at least monthly) to monitor for QTc prolongation; more frequent monitoring is warrant for patients on multiple QTc-prolonging drugs or in the setting of risk factors. In addition, such patients should have electrolytes checked regularly (baseline, at two weeks, and then at least monthly). (See
         <a class="local">
          'QT prolongation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurotoxicity
         </strong>
         – Forms of neurotoxicity associated with antituberculous drugs include peripheral neuropathy (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">
          cycloserine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ) and central nervous system toxicity (psychiatric effects [depression can occur with cycloserine or ethionamide; psychosis can occur with cycloserine, fluoroquinolones, or isoniazid], seizures [fluoroquinolones, linezolid, isoniazid, and carbapenems], and serotonin syndrome [linezolid]). (See
         <a class="local">
          'Neurotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ototoxicity and nephrotoxicity
         </strong>
         – The aminoglycosides and
         <a class="drug drug_general" data-topicid="9194" href="/z/d/drug information/9194.html" rel="external">
          capreomycin
         </a>
         can cause vestibular toxicity, auditory toxicity, nephrotoxicity, and electrolyte disturbances. Patients on these agents should have monthly assessments for vestibular and auditory toxicity, close monitoring of renal function and electrolytes, and therapeutic drug monitoring. (See
         <a class="local">
          'Ototoxicity'
         </a>
         above and
         <a class="local">
          'Nephrotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic effects
         </strong>
         – Hematologic abnormalities associated with antituberculous drugs may involve any cell line. The most common causes of hematologic abnormalities among the antituberculous drugs include
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ; these are summarized in the table  (
         <a class="graphic graphic_table graphicRef108484" href="/z/d/graphic/108484.html" rel="external">
          table 9
         </a>
         ). (See
         <a class="local">
          'Hematologic effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ophthalmic toxicity
         </strong>
         – Antituberculous drugs associated with optic nerve toxicity include
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9438" href="/z/d/drug information/9438.html" rel="external">
          ethionamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         .
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          Clofazimine
         </a>
         toxicity produces a pigmentary maculopathy and generalized retinal degeneration.
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         can cause a pan-uveitis that is reversible with dose adjustment. (See
         <a class="local">
          'Ophthalmic toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other adverse effects
         </strong>
         – Other adverse effects associated with antituberculous drugs include musculoskeletal effects, endocrine effects, and other effects. (See
         <a class="local">
          'Musculoskeletal effects'
         </a>
         above and
         <a class="local">
          'Endocrine effects'
         </a>
         above and
         <a class="local">
          'Other adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 2021; 57.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. WHO 2019 consolidated guidelines on drug-resistant tuberculosis treatment. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1 (Accessed on March 28, 2019).
         </li>
         <li class="breakAll">
          Curry International Tuberculosis Center. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition. CITC, Washington, DC 2016. http://www.currytbcenter.ucsf.edu/sites/default/files/tb_sg3_book.pdf (Accessed on July 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013; 62:1.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. SIRTURO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf (Accessed on April 05, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6:699.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Tuberculosis (TB). Treatment of Multidrug-Resistant Tuberculosis: Bedaquiline. https://www.cdc.gov/tb/publications/factsheets/treatment/bedaquiline.htm (Accessed on March 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrineau S, Lachâtre M, Lê MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu H, Xie L, Liu ZQ, et al. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. Int J Tuberc Lung Dis 2021; 25:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58:2979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omar SV, Ismail F, Ndjeka N, et al. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. N Engl J Med 2022; 386:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelwahab MT, Court R, Everitt D, et al. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrob Agents Chemother 2021; 65:e0268720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Deun A, Salim MA, Das AP, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther 2021; 110:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis 2021; 105:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med 2019; 7:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lardizabal AA, Khan AN, Bamrah Morris S, Goswami ND. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017. MMWR Morb Mortal Wkly Rep 2018; 67:996.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: Interim policy guidelines. WHO, Geneva 2014. http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf (Accessed on January 07, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021; 21:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirehwa MT, Court R, de Kock M, et al. Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrob Agents Chemother 2021; 65:e0027821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mugabo P, Mulubwa M. Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis. Br J Clin Pharmacol 2021; 87:3863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA. Quinolones and tuberculosis. Ann Pharmacother 1996; 30:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013; 188:858.
          </a>
         </li>
         <li class="breakAll">
          WHO 2007. Guidelines for the programmatic management of drug-resistant tuberculosis. http://www.who.int/tb/features_archive/xdr_mdr_policy_guidance/en/index.html (Accessed on May 11, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pletz MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008; 12:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifert M, Georghiou SB, Garfein RS, et al. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clin Infect Dis 2017; 65:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caminero JA, World Health Organization, American Thoracic Society, British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10:829.
          </a>
         </li>
         <li class="breakAll">
          WHO 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (Accessed on May 11, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devasia RA, Blackman A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21:253S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA, Phillips PPJ, Mitnick CD, et al. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019; 3:CD012836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntziora F, Falagas ME. Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review. Int J Tuberc Lung Dis 2007; 11:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grard S, Catho G, Valour F, et al. Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Open Forum Infect Dis 2015; 2:ofv175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelwahab MT, Wasserman S, Brust JCM, et al. Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. Antimicrob Agents Chemother 2021; 65:e0138121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tietjen AK, Kroemer N, Cattaneo D, et al. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. Br J Clin Pharmacol 2022; 88:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott AM, Foster SD. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection. Tuber Lung Dis 1996; 77:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krüüner A, Jureen P, Levina K, et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:2971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49:3192.
          </a>
         </li>
         <li class="breakAll">
          The Partners in Health Guide to the Medical Management of Multidrug-Resistant Tuberculosis, Rich ML (Ed), Partners in Health, Boston 2003.
         </li>
         <li class="breakAll">
          Report WHO/HTM/TB/2006.361. (World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin S, Furin J, Alcántara F, et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004; 125:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watt B, Edwards JR, Rayner A, et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber Lung Dis 1992; 73:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49:2816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijn SP, Zuur MA, Anthony R, et al. Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki Y, Kurashima A, Morimoto K, et al. [Experience of rapid drug desensitization therapy in the treatment of mycobacterial disease]. Kekkaku 2014; 89:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhari GK, Keren M, Dursun AB, et al. Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol. Ann Allergy Asthma Immunol 2015; 115:39.
          </a>
         </li>
         <li class="breakAll">
          National Institutes of Health. Vitamin B6: Recommended intakes. https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/#h2 (Accessed on August 12, 2016).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 488 Version 52.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31729908" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33243847" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33243847" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33243847" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8231410" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pharmacology of the antimycobacterial drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24157696" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24157696" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28529205" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30001994" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30001994" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30674381" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34886931" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24590481" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359333" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34986292" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33875426" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15137531" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605283" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33837535" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Treatment of Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30858211" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33684562" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670901" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Delamanid for multidrug-resistant pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30630778" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30188880" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30188880" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33587897" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34310215" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33620754" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876870" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Quinolones and tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10713001" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828024" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23927582" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23927582" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543673" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917230" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982764" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647445" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475735" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28331043" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837348" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fluoroquinolones, tuberculosis, and resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16898365" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of multidrug-resistant tuberculosis: evidence and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16898365" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Treatment of multidrug-resistant tuberculosis: evidence and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329799" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766835" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Fluoroquinolone-associated tendinopathy: a critical review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11642691" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Fluoroquinolone adverse effects and drug interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16776446" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070980" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30012767" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893466" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Linezolid for drug-resistant pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519090" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected]a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282348" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16857689" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19468028" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496332" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23075177" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719846" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34543098" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34622478" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22828481" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25622149" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25795076" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8733410" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20797644" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9593173" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937004" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048924" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048924" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048924" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15006956" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1901260" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1421344" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15980354" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Imipenem for treatment of tuberculosis in mice and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30455232" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24846578" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Therapeutic drug monitoring in the treatment of tuberculosis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821209" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17021358" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : An official ATS statement: hepatotoxicity of antituberculosis therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25730947" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : [Experience of rapid drug desensitization therapy in the treatment of mycobacterial disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25981840" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
